Strategic funding Position QLB Biotherapeutics as a high-potential partner for global biotech investors and contract research organizations seeking access to emerging cancer immunotherapy programs in early-stage to mid-stage development, emphasizing backing from Qilu Pharmaceutical and the plan to expand overseas R&D capacity.

Growth potential Emphasize the startup’s ambitious pipeline in solid tumors and hematologic cancers, highlighting opportunities for collaborations on preclinical to translational studies, co-development deals, and stage-appropriate licensing to accelerate product timelines.

Immunotherapy focus Leverage the core expertise in next-generation cancer immunotherapies to offer specialized partnerships in biomarker discovery, immune-oncology platform collaborations, and translational research services that align with market demand for innovative solid tumor and blood cancer solutions.

Strategic location Highlight Boston’s biotech ecosystem and the proximity to leading academic centers and contract research networks to propose collaborations, joint ventures, or sponsored research agreements that can accelerate IND-enabling work and clinical planning.

Financial signal Frame revenue visibility and funding backing as a foundation for longer-term collaboration models, proposing sponsored research, milestone-driven partnerships, and access to scalable manufacturing or process development services to support rapid progression of their candidates.